健康成人接种MDCK细胞培养灭活H7N9流感疫苗的安全性与免疫原性:一项I/II期前瞻性随机开放标签试验
在台湾三家医院开展的I/II期前瞻性随机开放标签试验中,20-60岁健康成人序贯入组I期(n=40)和II期(n=160),随机接受2剂全病毒H7N9疫苗(15或30μg血凝素抗原,含或不含氢氧化铝佐剂),间隔21天。大多数不良事件轻微短暂,无死亡或疫苗相关严重不良事件;30μg血凝素抗原组免疫应答高于15μg组,含佐剂30μg组免疫应答最高。
要点
- 200名随机受试者中193名(96.5%)完成2剂接种并纳入安全性意向性分析,190名(95%)纳入免疫原性符合方案分析。
- 大多数不良事件轻微且短暂,未报告死亡或疫苗相关严重不良事件。
- 含氢氧化铝佐剂30μg血凝素抗原组免疫应答最高,血凝抑制抗体滴度、血清保护率、血清转化率和血清转化因子分别为36.2、64.6%、64.6%和5.7。
核心结论
- 含30μg血凝素抗原和氢氧化铝佐剂的H7N9流感疫苗在20-60岁成人中具有免疫原性和安全性。
研究设计与样本
- I/II期前瞻性随机开放标签试验,2015年4月7日至2016年5月27日在台湾三家医院序贯入组20-60岁健康成人,I期n=40、II期n=160,随机接受2剂全病毒H7N9疫苗(15或30μg血凝素抗原,含或不含氢氧化铝佐剂),间隔21天。
主要发现
- 200名随机受试者中193名(96.5%)接受2剂研究疫苗并纳入安全性意向性分析,190名(95%)纳入免疫原性符合方案分析。
- 大多数不良事件轻微且短暂,未报告死亡或疫苗相关严重不良事件。
- 接受30μg血凝素抗原制剂的组免疫应答总体高于接受15μg血凝素抗原制剂的另外两组。
- 接受2剂含佐剂30μg血凝素抗原疫苗的受试者免疫应答最高,血凝抑制抗体滴度、血清保护率、血清转化率和血清转化因子分别为36.2、64.6%、64.6%和5.7。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We conducted a phase I/II clinical trial to evaluate the safety and immunogenicity of a Madin-Darby canine kidney (MDCK) cell-grown inactivated H7N9 influenza vaccine for pandemic preparedness purposes. METHODS: Between April 7, 2015 and May 27, 2016, healthy adults aged 20-60years were enrolled sequentially in phase I (n=40) and phase II (n=160) from three hospitals in Taiwan and randomized to receive 2 doses of whole-virus H7N9 vaccine (15 or 30μg hemagglutinin antigen (HA) with or without an aluminum hydroxide adjuvant) at 21-day intervals. Safety up to 180days and changes in hemagglutinin inhibition (HI) titers at 21days after each vaccination were determined. RESULTS: Of the 200 randomized subjects, 193 (96.5%) received 2 doses of the study vaccine and were included in the intention-to-treat analysis for safety, and 190 (95%) were included in the per-protocol analysis for immunogenicity. Most adverse events were mild and transient; no death or vaccine-related serious adverse events were reported. Overall, higher immune responses were observed in the groups administered with 30μgHA formulation than in the other two groups administered with 15μgHA formulation. The highest immune response was observed in subjects who received 2 doses of the adjuvanted vaccine containing 30μgHA with HI titer, seroprotection rate, seroconversion rate, and seroconversion factor of 36.2, 64.6%, 64.6% and 5.7, respectively. CONCLUSIONS: Our study demonstrated that the H7N9 influenza vaccine containing 30µgHA with aluminum hydroxide adjuvant was immunogenic and safe in adults aged 20-60years. CLINICALTRIALS.GOV identifier: NCT02436928.
引用
- Wu UI, Hsieh SM, Lee WS, et al. Safety and immunogenicity of an inactivated cell culture-derived H7N9 influenza vaccine in healthy adults: A phase I/II, prospective, randomized, open-label trial. Vaccine. 2017. PMID: 28668573. doi:10.1016/j.vaccine.2017.06.044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。